Safety and Efficacy of Deucravacitinib in Japanese Patients With Moderate to Severe Plaque Psoriasis: 5-Year Analysis of the Phase 3 POETYK PSO-1, PSO-4, and Long-Term Extension Trials

By afschroeder • August 7, 2026

Okubo Y, Morita A, Tada Y, Imafuku S, Armstrong AW, Blauvelt A, Vaile J, Popmihajlov Z, Li J, Sawant R, Habiro K, Tsuritani K, Ohtsuki M. Safety and Efficacy of Deucravacitinib in Japanese Patients With Moderate to Severe Plaque Psoriasis: 5-Year Analysis of the Phase 3 POETYK PSO-1, PSO-4, and Long-Term Extension Trials. J Dermatol. 2026 Aug 5. doi: 10.1111/1346-8138.70392. Epub ahead of print. PMID: 42557591.

Tags: Dermatology, deucravacitinib, long‐term, phase 3, psoriasis, Publications, safety, tyrosine kinase 2 inhibitor

Tralokinumab Versus Dupilumab for the Treatment of Atopic Dermatitis with Moderate-to-Severe Hand Involvement: A Matching-Adjusted Indirect Comparison

Armstrong A, Kircik L, Metelitsa A, Warren RB, Rodriguez A, Volc S, Issa N, Chovatiya R, von Eyben R, Festini T, Johansen P, Ehst B.[...]

Low-Dose Oral Minoxidil Use for Pediatric Hair Disorders: An International Consensus Statement

Akiska YM, Fu J, Castelo-Soccio L, Mathes E, Mirmirani P, Jamerson T, Sibbald C; and The Pediatric Low-Dose Oral Minoxidil Consensus Expert Group; Spagnol Abraham[...]

Robustness of Network Meta-Analysis in Chronic Plaque Psoriasis-Reply

Armstrong AW, Nong Y, Merola JF. Robustness of Network Meta-Analysis in Chronic Plaque Psoriasis-Reply. JAMA Dermatol. 2026 Sep 23. doi: 10.1001/jamadermatol.2026.3645. Epub ahead of print.[...]